Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”
This article was originally published in The Pink Sheet Daily
Executive Summary
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech could do so with an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.